{"name":"Arxx Therapeutics","slug":"arxx-therapeutics","ticker":"","exchange":"","domain":"","description":"Arxx Therapeutics is a biotechnology company focused on developing innovative therapies for patients with unmet medical needs. The company's lead candidate, AX-202, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTC1ENkVrQk1oek5qWVZ4OEVJbU9qcmlHR2w3bVNfQmxhX3pJV2xyYlMxY21JUWZILWw5d0djYjRWNWwyblJ2SENIcDhVQ2M3elBscFZfQ2hLcFN6dklFQnhpZ05tVFItSUk2OUF2N2FBSlJwMVVwQ2F4NWcxRWVkbk90NVFwb3M?oc=5","date":"2024-10-24","type":"trial","source":"Clinical Trials Arena","summary":"Calluna completes CAL101 Phase I clinical study for fibrotic conditions - Clinical Trials Arena","headline":"Calluna completes CAL101 Phase I clinical study for fibrotic conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxOTU11QzdwdnZuRmpLRUtXUTltVkdYWGhUVG5hNzdVRjZYRF9EaTdQamNWbmlESXB4QmhZRnQtRTk2NEhzd1owdDItSXFGMTdtS2ZSUEdTRVByNVZ0TnlKc2xHOTJOSVRRRVV0QTNybHc4WnkxaE04VUhlcTRsUXgzY2Z3NHZVWWxnbnFnN3BXMzhkRDEwcGd5NHdicDRSLVVrNEk3SHNjOVN1c29UZTgzOEpEQm13QXEyY3c5a0hTWUtwcnFPNVJ6SlRxTXU3OVNkOWxKdEM0eTVSaXR2bkNDWUg4S0xJOGRwNlpJWW9hSG9zMkxzamV1NW9YYTlac1BuTXN2Nk1EbTdNR3NnVnBOdXUyeHdmcUFsQl8zRHR3cGtNWmZNWUxYTUplemw?oc=5","date":"2024-10-23","type":"trial","source":"Business Wire","summary":"Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications - Business Wire","headline":"Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9GU3Mya294RXRDc3ZOdW1vWnpYVHVfOU53amc1VnVQVTVYV0gtN3dmYVFqcGF5STQ4RVBIcV83MWVFSHp2UTVaNTFTaWNxR2FQZHpDUndEVFRTQ19VX2psSGZSZWFXRmk3aUR0UWlTTmk0aGk3eGE3a1p3?oc=5","date":"2024-10-09","type":"pipeline","source":"Contract Pharma","summary":"Calluna Pharma Names CEO - Contract Pharma","headline":"Calluna Pharma Names CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQLWZBMktTdXUxWThpMU52bGw2Wlc2cXY5VTBqb1F1M3dPazVqLS04dGdKcl9OVGtHS01QTE9TR2pXSC0tZWVVQXR2eWN2LTJMWi11U0xJN2dHYnhJN044MVYtZ29RVE9FUHRJX1F2ZEVNMUFTdlNpWHZJZ0VkNk9PMHMySG93UTdERU9pVldGVkZyLWtrdXdGbW9qVENKNEJiQ3YwYXVfRVRPODd3MVgwYTJ1T1VrRWpxeVFPLVlJcER4Q00yV3BTaEJrTUpxSlJUNFZhYThlTmU4WXB5alVXN1EyZHZpVU5qUWdF?oc=5","date":"2024-08-07","type":"pipeline","source":"respiratory-therapy.com","summary":"Calluna Pharma Launches with €75M for Inflammatory and Fibrotic Disease Therapies - respiratory-therapy.com","headline":"Calluna Pharma Launches with €75M for Inflammatory and Fibrotic Disease Therapies - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQ29VeDFZR0hqaXp5QnlmRHpkdERkY1ZnVzdaYXFzb2xsc0cwbVNrUi1mR0RPS0l3Wkx0S3JDS1p4Q192MEc0LUc0LXEwa2J2TjByUTY1Y3dMbkhHY3dpaktZS3FtZ3FvRTZtOGdUTWZNWnlrTDdCWVNkWUVKdUZFT3BENGhrblFwcDVuOW1aazFDaHpLWmtCVENqZHZCNjBNZzJLTkpiSUJIQnF0SWwxaXlHRm9iUU9wMUFJ?oc=5","date":"2024-02-02","type":"pipeline","source":"BioWorld News","summary":"Born of Oxitope and Arxx, Calluna emerges with €75M series A for immunology push - BioWorld News","headline":"Born of Oxitope and Arxx, Calluna emerges with €75M series A for immunology push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOOW9SUEo0WnViZVJZeWx4RDV2WHFDUUFDVFhtOVZoMUs1cTMySHB1T2JpT01VRUh1TVNIVTlIMklWUnBaYndNajlwM25qOFdVbnk4djlJbzFFT2M3YVllbnBSeEhPZFhzT1NJdTAwaXhkTFZscmpqU3REUFBSdHVrOHg1VExaRFZUMkZEV3Y4LXZaNWstc0Y4M1dXcWswVnkyVVNlTzd4a18?oc=5","date":"2024-01-24","type":"pipeline","source":"PharmaTimes","summary":"Calluna Pharma announces €75m series A financing for immunological diseases - PharmaTimes","headline":"Calluna Pharma announces €75m series A financing for immunological diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNMk94SXNlUS1uOTBNeDBIa09qaVM1UjRtaEtESEVrdHFFRVFSWTlYZ0hTVDVjcWQyWWFST0l6c29NSWVsNEljeTBpd3ZHX25TTjZuNlNVczB2RGhNNFdVWEo3LWxyUGh0VjBTLXJGdDlsb0k3ZFZ6R3VLSXlHc0dwSlB6d2dxaVNURldLc0U0aWdMdE1nSFZLMmtkUnZlN2tseUxiNl9xMHBucTQ0Y3NsU0pBU3J5M1cweUpXQjlXUzRxcHZPbXkzMmhXZkNNdk5rcS1EZG4tOUdxWmcwU0NGcDBmeFZUc2U2YTlLVG4tanVfbE9vWFdjeWZGMWhXMWlfUW1zYnNOVS11VTBZY3k5dWtuOXNZb2F2VlpkTXBjWQ?oc=5","date":"2024-01-23","type":"pipeline","source":"Business Wire","summary":"Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases - Business Wire","headline":"Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOSVIxQ2pQekV5RjRKMVdtVkJtRFYwMzZrUUNwSnFmNEVRcVIzRVZXUjBoRlRMZms2cjhteVphVnFoRnJjV0FCLUZwbXI1MmdFQnFnbXROajZiSjBjQXdWaktKb0VpNnJ4Zm95em9BV19QNzdER21qVDZNVndSR3JwajlLemQyVGV5bFZFd0ZvRFpHWnFrWllXT2s3cUszQlVWWmU5YzVyaG1xN185eFBQNDdEX0c3YUNGUGFiYUhn?oc=5","date":"2024-01-23","type":"pipeline","source":"Pharmaceutical Technology","summary":"Newly launched Calluna raises $81m to advance monoclonal antibody pipeline - Pharmaceutical Technology","headline":"Newly launched Calluna raises $81m to advance monoclonal antibody pipeline","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}